Nevertheless, GPM6A was found to activate the Smad pathway in HCC cells [106], while the Smad signaling pathway is a double‐edged sword for promoting and suppressing cancer in the treatment of malignant tumors [112, 116]. Here, GPM6A is linked to hepatocellular carcinoma.